Under the agreement, participating states will receive “discounts and rebates” from the drugmakers if the treatments don’t ...
Medicaid is doing a novel payment system for the new, promising and expensive sickle cell treatment. It may become a model ...
Rilzabrutinib is an investigational, oral reversible Bruton tyrosine kinase inhibitor. The Food and Drug Administration (FDA) has granted Orphan Drug designation to rilzabrutinib for the treatment of ...
Memantine, a long-approved and cost-effective drug used to treat Alzheimer's disease, could also benefit patients with sickle ...
Please provide your email address to receive an email when new articles are posted on . ASH issued sickle cell disease research priorities that address seven key focus areas. Topics include end-organ ...
Sickle cell awareness month, observed annually in September, is a time to raise awareness about sickle cell disease, a genetic blood disorder that affects millions of people worldwide. The Pfizer drug ...
Meghana Keshavan covers biotech and contributes to The Readout newsletter. SAN DIEGO — Pfizer’s abrupt withdrawal of its sickle cell drug Oxybryta over safety concerns was called “tone deaf” during a ...
This electron microscope image provided by the National Institutes of Health in 2016 shows a blood cell altered by sickle cell disease, top. (National Center for Advancing Translational Sciences ...
A new gene therapy for people who can have a stem cell transplant but do not have a suitable donor has been approved.
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. In the years since the approval of Imbruvica for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results